Evidence map›Paper›PMID 29868829›Full record

ArticleThe Journal of infectious diseases2018

Group B Streptococcus Biofilm Regulatory Protein A Contributes to Bacterial Physiology and Innate Immune Resistance.

Kathryn A Patras, Jaclyn Derieux, Mahmoud M Al-Bassam, Nichole Adiletta, Alison Vrbanac, John D Lapek, Karsten Zengler, David J Gonzalez, Victor Nizet

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 52 citations in OpenAlex.

  1. Antibacterial Activity of Rosmarinic Acid AgainstAnimals : an open access journal from MDPI · 2026
    Article
  2. Article
  3. Article
  4. Matrine AttenuatesMicroorganisms · 2025
    Article
  5. Identification of glyoxalase A in group BInfection and immunity · 2025
    Article
  6. Review
  7. Identification of Glyoxalase A in Group BbioRxiv : the preprint server for biology · 2024
    Article
  8. Re-framing the importance of Group BInfection and immunity · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Group BScience advances · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Novel Models ofMicroorganisms · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kathryn A PatrasDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California-San Diego, La Jolla.
Jaclyn DerieuxDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California-San Diego, La Jolla.
Mahmoud M Al-BassamDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California-San Diego, La Jolla.
Nichole AdilettaDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California-San Diego, La Jolla.
Alison VrbanacDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California-San Diego, La Jolla.
John D LapekDepartment of Pharmacology, School of Medicine, University of California-San Diego, La Jolla.
Karsten ZenglerDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California-San Diego, La Jolla.
David J GonzalezDepartment of Pharmacology, School of Medicine, University of California-San Diego, La Jolla.
Victor NizetDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California-San Diego, La Jolla.
University of California, San Diego · US

Funding

Siglec Modulation of Inflammatory ResponsesP01HL107150 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LE, DZUNG T · 2011 to 2017
$18.0M
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki DiseaseU54HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIGAM, SANJAY K · 2016 to 2018
$2.2M
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki DiseaseP50HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAPPARELLI, EDMUND VINCENT, NIZET, VICTOR · 2019 to 2020
$1.4M
Transcriptional response of a skin microbiome transplantR21AR071731 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZENGLER, KARSTEN B · 2017 to 2017
$341k
NHLBI NIH HHS P01 HL107150NIAMS NIH HHS R21 AR071731NICHD NIH HHS P50 HD090259NICHD NIH HHS U54 HD090259
6 · The paper itself

Abstract

Background: Streptococcus agalactiae (group B Streptococcus [GBS]) asymptomatically colonizes approximately 20% of adults; however, GBS causes severe disease in susceptible populations, including newborns, pregnant women, and elderly individuals. In shifting between commensal and pathogenic states, GBS reveals multiple mechanisms of virulence factor control. Here we describe a GBS protein that we named "biofilm regulatory protein A" (BrpA) on the basis of its homology with BrpA from Streptococcus mutans. Methods: We coupled phenotypic assays, RNA sequencing, human neutrophil and whole-blood killing assays, and murine infection models to investigate the contribution of BrpA to GBS physiology and virulence. Results: Sequence analysis identified BrpA as a LytR-CpsA-Psr enzyme. Targeted mutagenesis yielded a GBS mutant (ΔbrpA) with normal ultrastructural morphology but a 6-fold increase in chain length, a biofilm defect, and decreased acid tolerance. GBS ΔbrpA stimulated increased neutrophil reactive oxygen species and proved more susceptible to human and murine blood and neutrophil killing. Notably, the wild-type parent outcompeted ΔbrpA GBS in murine sepsis and vaginal colonization models. RNA sequencing of ΔbrpA uncovered multiple differences from the wild-type parent, including pathways of cell wall synthesis and cellular metabolism. Conclusions: We propose that BrpA is an important virulence regulator and potential target for design of novel antibacterial therapeutics against GBS.

Indexed as

AnimalsBacterial ProteinsBiofilmsCell LineFemaleHost-Pathogen InteractionsHumansImmunity, InnateMiceNeutrophilsStreptococcal InfectionsStreptococcus agalactiaeBacterial Proteins

Identifiers

PMID29868829
PMCPMC6173572
OpenAlexW2806714940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.